Research Kit detects and quantifies DNA damage.
Press Release Summary:
OxyFLOW(TM) utilizes fluorescent 8-oxoguanine binding protein in flow cytometric assay for detecting and quantifying oxidative DNA damage to lympho-hematopoietic cells resulting from stress, xenobiotics, and administration of drugs. Availability of direct-conjugated antibodies directed to membrane antigens allows identification of oxidative DNA damage in subpopulations of cells. Kit can also be used for toxicity testing and environmental biomonitoring.
Original Press Release:
HemoGenix(TM) Announces the Release of the OxyFLOW(TM) Research Kit in Collaboration With Biotrin International Ltd. of Dublin, Ireland
OxyFLOW(TM) is an Assay for Detecting and Quantifying Oxidative DNA Damage to Many Different Types of Lympho-Hematopoietic Cells From Both in Vivo and in Vitro Sources and From Several Species Including Human, Non Human Primate, Dog, Rat, and Mouse Using Flow Cytometry
In Addition to Basic Research, OxyFLOW(TM) Can Be Used for Toxicity Testing, Pharmacological and Chemical Screening and Occupational and Environmental Biomonitoring
COLORADO SPRINGS, Colo., Feb. 7 -- HemoGenix(TM) has now made available its proprietary OxyFLOW(TM) Research Kit. HemoGenix Inc., in collaboration with Biotrin International Ltd., has developed a flow cytometric assay for detecting and quantifying oxidative DNA damage to lympho- hematopoietic cells. OxyFLOW(TM) is an assay platform that detects oxidative DNA damage as a result of stress, xenobiotics and the administration of drugs. Reactive oxygen species (ROS) produced under these conditions are particularly damaging to DNA. The result of oxidative DNA damage is the formation of 8-oxoguanine adducts.
OxyFLOW(TM) utilizes a fluorescent 8-oxoguanine binding protein in a simple flow cytometric test for lympho-hematopoietic cells. In addition, the availability of direct-conjugated antibodies directed to membrane antigens allows identification of oxidative DNA damage in specific subpopulations of cells.
HemoGenix(TM), a contract research and development company, is the leader in stem cell hemotoxicology, specializing in testing new drug candidates that are in the process of being developed by biotechnology and pharmaceutical companies for their toxic side effects on stem cells and other proliferating cells of the blood-forming system. HemoGenix(TM) focuses on non-invasive, physiological, in vitro cell-based screening and monitoring assays to help detect, quantify and predict the effect of compounds on the blood-forming system. To do this effectively and rapidly, HemoGenix(TM) developed the HALO(TM) (Hematopoietic/Hemotoxicity Assays via Luminescence Output) Platform.
HemoGenix(TM) can draw on over 200 tests and procedures in its armory to help drug development companies detect and analyze potential toxic side effects. The company also develops its own new tests to provide the biotechnology and pharmaceutical community with new and improved tools to detect hemotoxicity. HemoGenix(TM) is the only company in the world that has made this its single specialty.
Biotrin International develops, manufactures and promotes propriety biomarker assays that have known origins and functions and that enable toxic or other effects to be localized to precise cell groups or tissues. The Biotrin SMARTASSAYS range of biomarkers assays enables effects to be identified earlier and at lower doses of test substance than using traditional biomarkers. www.Biotrin.com
More information is available at www.hemogenix.com and www.Biotrin.com
